Medpace Hldgs Analyst Ratings
UBS Downgrades Medpace(MEDP.US) to Hold Rating, Cuts Target Price to $350
Maintaining Hold on Medpace Holdings Amid Market Headwinds and Revised Growth Expectations
Medpace Downgraded to Neutral From Buy at UBS
Jefferies Downgrades Medpace Holdings to Hold From Buy, Price Target Is $345
Medpace Holdings Is Maintained at Outperform by Baird
Baird Maintains Medpace(MEDP.US) With Buy Rating, Cuts Target Price to $413
Medpace Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Medpace Holdings (MEDP)
Truist Financial Maintains Medpace(MEDP.US) With Hold Rating, Maintains Target Price $415
Truist Financial Initiates Medpace(MEDP.US) With Hold Rating, Announces Target Price $415
Medpace Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP) and Roche Holding AG (OtherRHHVF)
Medpace Holdings Price Target Cut to $336.00/Share From $395.00 by Deutsche Bank
A Quick Look at Today's Ratings for Medpace(MEDP.US), With a Forecast Between $430 to $480
Deutsche Bank Adjusts Medpace Holdings Price Target to $336 From $395, Maintains Hold Rating
Medpace Holdings: Caution Ahead Despite Strong Performance – Hold Rating Justified
Medpace Hldgs Analyst Ratings
TD Cowen Maintains Medpace(MEDP.US) With Buy Rating, Maintains Target Price $452
TD Cowen Remains a Buy on Medpace Holdings (MEDP)